SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-04
👔
Inhibitor Therapeutics, Inc.
@INTI_InsiderForm 4 Filing: ODONNELL FRANCIS E JR Acquires (Grant) shares of $INTI
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
Inhibitor Therapeutics, Inc.
Ticker: $INTI
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-05-04
Shares: 50,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, ODONNELL FRANCIS E JR, holds the title of Chief Executive Officer at Inhibitor Therapeutics, Inc..
On 2026-05-04, the insider transacted 50,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
ODONNELL FRANCIS E JR (Chief Executive Officer) was granted $0 of $INTI
Post-Transaction Position: 150,000 shares
SEC Accession No: 0001493152-26-035950 (CIK: 1066040)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.